By Christy Santhosh (Reuters) -AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline ...

China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab.

AbbVie, the maker of three migraine treatment options, launched a contest to support people whose migraines create obstacles in reaching their goals.

AbbVie (NYSE:ABBV) is scheduled to announce its earnings on Friday, April 25, 2025. Currently, the company holds a market capitalization of $307 billion. Over the past twelve months, AbbVie ...

Exclusive: AbbVie spent far more than other pharma companies to promote its drugs as it faced the end of patent protection for its blockbuster treatment Humira.

AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025. Management will participate in a fireside chat at 10:20 a.m. Central time.

AbbVie added the FDA had not identified issues with the therapy's safety or efficacy and did not request additional trials. The therapy ABBV-951 is a version of carbidopa-levodopa, the standard of ...

Analysts have provided the following ratings for AbbVie (NYSE:ABBV) within the last quarter: These 8 analysts have an average price target of $163.0 versus the current price of AbbVie at $154.9375 ...

The average AbbVie price target of $161.73 suggests a modest 3.47% upside potential from current levels.ConclusionWhile Humira continues to be AbbVie’s crown jewel, investors will be keen to ...

(Reuters) -U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion. Capstan develops CAR-T therapies, a type of ...

(Reuters) -U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to $2.1 billion, expanding its pipeline with experimental treatments ...